Graft versus host disease

This early-phase trial tests whether a bone marrow transplant from a partially matched relative can safely cure chronic granulomatous disease (CGD), a condition that causes severe infections and inflammation. Four people aged 4 to 65 with CGD and no perfect donor will receive che…

This study follows patients who have already been taking ruxolitinib alone or with panobinostat in earlier trials and are still benefiting. Researchers will track side effects over time to see how safe these drugs are for long-term use. About 296 participants with conditions like…

This early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.

This early study tests whether combining a low-dose steroid with the drug ruxolitinib can better control grade II acute graft-versus-host disease (GVHD) after a stem cell transplant. GVHD occurs when donor immune cells attack the recipient's body. The trial includes 30 people wit…

This study tests a new oral drug called alvelestat (MPH966) in adults who have lung damage (bronchiolitis obliterans syndrome) after a stem cell transplant. The drug aims to block an enzyme that may cause lung injury. The trial has two parts: first to find the safest and most eff…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This early-phase trial tests whether d-MAPPS eye drops can safely and effectively treat chronic ocular graft-versus-host disease (oGVHD), a painful dry eye condition that can occur after a stem cell transplant. One adult participant will use the drops or a placebo four times dail…

This study tests a new treatment called CYP-001 for people who develop a severe immune reaction (graft versus host disease) after a stem cell transplant. About 60 participants will receive either CYP-001 plus standard steroids or a placebo plus steroids. The goal is to see if add…

This Phase 2 trial tests whether adding axatilimab to the standard drug ruxolitinib works better for people newly diagnosed with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. About 130 participants aged 12 and older will …

This trial tests whether infusions of white blood cells from healthy, unrelated donors can help treat solid cancers that have not responded to standard treatments. About 29 patients will receive daily infusions over 1-2 weeks, and their tumors will be checked after 3 months. The …

This study tests a stem cell transplant using cells from a half-matched family donor, combined with low-dose radiation and drugs to prevent rejection, for adults with severe sickle cell disease or beta-thalassemia. The goal is to see if this gentler approach can replace the disea…

This study tests a stem cell transplant from a half-matched relative (haploidentical donor) for adults with severe sickle cell disease. The goal is to see if a gentler conditioning regimen can reduce complications like graft rejection and graft-versus-host disease. Participants r…

This phase 2 trial tests whether the drug itacitinib, given with standard care, can prevent graft-versus-host disease (GVHD) in people who receive a donor stem cell transplant for blood cancers. GVHD happens when the donor cells attack the patient's body. The study includes 31 ad…

This study aimed to see if a special type of stem cell (hAESC) could safely prevent acute graft-versus-host disease in people receiving a stem cell transplant for blood cancer. It was designed for adults at high risk of this complication. However, the study was withdrawn before a…

This study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach uses chemotherapy, total body radiation, and a drug called cyclophosphamide after the transplant to prevent graft-versus-host disease, where donor cells attack the…

This study tests a new treatment called MC0518 (made from donor cells) in children who have severe graft-versus-host disease (GvHD) after a stem cell transplant and did not get better with steroids. GvHD happens when the donor's immune cells attack the child's body. The trial com…

This study tests a new drug called axatilimab against the best current treatments for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Participants must be at least 12 years old and have tried at least two prior treatments withou…

This study tests an oral enzyme called SYN-004 in adults who have received a stem cell transplant and need intravenous antibiotics for fever. The enzyme is designed to break down antibiotics in the gut, protecting the natural bacteria there. Researchers will check safety, whether…

This study tests whether a lower-dose combination of two drugs (PTCy and ruxolitinib) can prevent graft-versus-host disease (GVHD) in older adults receiving a stem cell transplant for blood cancer. About 56 participants will receive the treatment and be monitored for survival wit…

This phase II trial tests a special stem cell transplant that removes immune T-cells from the donor's blood to lower the risk of graft-versus-host disease (GVHD), a serious complication where the donor cells attack the patient's body. About 50 adults with myelodysplastic syndrome…

This study tests whether adding the drug abatacept to standard care can prevent graft-versus-host disease (GVHD) in children receiving stem cell transplants from unrelated donors. GVHD occurs when donor cells attack the patient's body, causing serious illness. The trial will enro…

This phase 2 trial tests whether daily low-dose injections of interleukin-2 (IL-2) can help control chronic graft-versus-host disease (cGVHD) in 35 people who did not respond to steroids. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack t…

This study aimed to test the safety and effectiveness of the oral drug belumosudil in Black, Native American, and Pacific Islander patients aged 12 and older with chronic graft-versus-host disease (cGVHD) who had already tried at least two other treatments. The goal was to see if…

This study tests a cream containing ruxolitinib, a drug that targets inflammation, for treating a chronic skin condition called graft-versus-host disease (GVHD) that can occur after a stem cell transplant. About 24 participants will apply the cream to one side of their body and a…

This early-phase trial tests the safety of combining donor anti-inflammatory Treg cells with low-dose Interleukin-2 (IL-2) for people with chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. cGVHD is a complication after a stem cell or bone marrow transpl…

This study tests a new combination of three drugs (cyclophosphamide, abatacept, and tacrolimus) given at lower doses to prevent graft-versus-host disease (GVHD) in 27 adults receiving a stem cell transplant from a half-matched donor. GVHD is a serious condition where donor cells …

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers. Researchers are first finding the best dose of vor…

This phase 2 trial tests whether adding the drug tocilizumab to a standard transplant regimen can prevent graft failure and graft-versus-host disease in people with blood cancers receiving a special type of bone marrow transplant. The study involves 21 participants and aims to re…

This study tests a drug called axatilimab in Japanese patients with chronic graft-versus-host disease (cGVHD) that has not improved after at least two prior treatments. cGVHD is a complication of stem cell transplants where donor cells attack the patient's body. The goal is to se…

This phase II trial tests whether the drug ustekinumab (Stelara) can prevent acute graft-versus-host disease (GVHD) in 116 adults receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. Ustekinumab aims to calm this immune…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can reduce side effects while still preventing the donor cells from attacking the recipient's body. The trial includes 105 people aged 15-65 with blood cancers like leukemia or…

This study tests a new tablet called TQ05105 in 45 adults with moderate to severe chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. The drug works by blocking a protein pathway involved in inflammation. The goal is to find the right dose and see if it c…

This study aimed to see if lower doses of chemotherapy drugs, with or without radiation, could safely prepare children and adults with SCID for a stem cell transplant. The goal was to help the donor cells take hold while avoiding severe side effects. However, the trial was withdr…

This study tests whether daily intravenous omega-3 fatty acids (fish oil) can reduce the risk and severity of acute graft-versus-host disease (aGVHD) in 30 adults receiving a stem cell transplant. Participants get omega-3 infusions from before transplant until about 35 days after…

This early-phase study tests a new treatment called CD6-CAR Tregs for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. The treatment uses specially engineered immune cells from a donor to help control the immune attack on the pat…

This study was designed to give people who had a stem cell transplant and developed low blood cell counts (anemia, low platelets) continued access to the drug fostamatinib. Only those who responded well in a prior study were eligible. The goal was to see if they could maintain st…

This study tests a drug called acalabrutinib in 51 adults with moderate to severe chronic graft-versus-host disease (GVHD), a complication after a stem cell transplant. The goal is to see if the drug can control the disease when steroids have stopped working. Participants take th…

This study offers continued access to ibrutinib for people with certain blood cancers or graft-versus-host disease who completed earlier ibrutinib trials and are still benefiting from the drug but cannot get it commercially. About 297 participants will receive ibrutinib while res…

This study tests whether adding the drug belumosudil to standard steroids helps control chronic graft-versus-host disease (cGVHD) better than steroids alone. cGVHD is a serious condition where donor immune cells attack the recipient's body after a stem cell transplant. About 260 …

This study tests an oral drug called TDI01 in 60 adults with moderate to severe chronic graft-versus-host disease (GVHD), a complication of stem cell transplants. Participants have already tried 1 to 5 other treatments without success. The trial has two phases: the first checks s…

This early-phase trial aimed to test whether adding the drug 5-azacytidine (AZA) to standard steroid treatment could protect gut stem cells in patients with gastrointestinal graft-versus-host disease (GVHD), a serious complication after a donor stem cell transplant. The study pla…

This study tests whether giving patients a transplant of healthy gut bacteria (from donated stool) can prevent severe graft-versus-host disease (GVHD) after a stem cell transplant. GVHD is a serious complication where donor immune cells attack the patient's body. The trial involv…

This study tests whether a probiotic called Lactobacillus plantarum can prevent a serious complication called graft-versus-host disease (GvHD) in the gut of children receiving a donor stem cell transplant. About 173 children with blood cancers or other conditions are taking the p…

This study tests whether a group-based behavioral program called Horizons can improve quality of life and coping skills in adults with chronic graft-versus-host disease (cGVHD), a common complication after stem cell transplant. The program involves 8 weekly video sessions with a …

This study tests whether a telehealth palliative care program is practical and well-liked by people with moderate to severe chronic graft-versus-host disease (cGVHD), a long-term complication after a stem cell transplant. Ten adults will receive up to three video-based palliative…

This study is testing whether a mobile app called Horizons can help adults with chronic graft-versus-host disease (a long-term complication after a bone marrow transplant) manage their symptoms and improve their quality of life. Twenty participants will use the app for about six …

This study tests whether 30 sessions of UVA-1 light therapy can improve daily life for people with scleroderma, morphea, or skin hardening from graft-versus-host disease. Thirty adults will report how their symptoms affect everyday tasks before and after treatment. The goal is to…

This study tests a telehealth program called Horizons for adults who have had a stem cell transplant and developed moderate to severe chronic graft-versus-host disease (GVHD). The program uses video sessions and questionnaires to help patients cope and follow their treatment plan…

This study tests a mobile app called Horizons designed to help people with chronic graft-versus-host disease (GVHD) after a stem cell transplant. The app aims to improve quality of life, reduce symptoms, and support coping. About 120 adults with moderate to severe chronic GVHD wi…

This study aims to create a symptom questionnaire specifically for children and teens living with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Current symptom scales are designed for adults, but children may describe their symptoms differently. Research…

This study examines tissue samples from patients who developed graft-versus-host disease (GVHD) after a stem cell transplant. Researchers use a technology called nCounter to measure the activity of 800 immune-related genes in these samples. The goal is to identify a unique molecu…

This pilot study aimed to see if giving a logbook to patients hospitalized for a stem cell transplant could help reduce feelings of isolation and psychological stress. The study was withdrawn before enrolling any participants, so no results are available. It was planned at the Un…

This study looks at whether new guidelines from the National Institutes of Health can help doctors better diagnose and track chronic graft-versus-host disease (GVHD), a common complication after stem cell transplants. Researchers are following 601 patients over several years, col…

This study involves 383 people who have chronic graft-versus-host disease (GVHD) after a stem cell transplant. Researchers are developing and testing new ways to measure whether a treatment is working, including a symptom-based activity index and a score that predicts long-term s…

This study aims to better understand what causes inflammatory bowel disease (IBD), graft-versus-host disease (GVHD), and other gut problems by analyzing blood and tissue samples from 1,000 patients. Researchers will use advanced lab techniques to track immune system changes over …

This study looks at how different types of immune cells in the skin, called dendritic cells, are involved in graft-versus-host disease (GVHD) after a bone marrow transplant. Researchers will take small skin samples and blood from 22 adults with acute or chronic skin GVHD. The goa…

This study looks at how changes in gut bacteria and their byproducts after a stem cell transplant might influence the development of graft-versus-host disease (GVHD), a serious complication. Researchers will collect stool and blood samples from 88 transplant recipients and their …

This study looks at whether the time when stem cells are given to blood cancer patients after a donor transplant affects their risk of developing acute graft-versus-host disease (aGVHD), a serious complication where donor cells attack the patient's body. About 198 patients aged 1…

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…